Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications

Stock Information for Reviva Pharmaceuticals Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Reviva Pharmaceuticals Holdings Inc.

Reviva Announces Letter to Shareholders
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.